78,806 Shares in Doximity, Inc. (NASDAQ:DOCS) Bought by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. purchased a new position in shares of Doximity, Inc. (NASDAQ:DOCS) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 78,806 shares of the company’s stock, valued at approximately $4,207,000.

Several other institutional investors also recently bought and sold shares of the stock. FMR LLC increased its position in Doximity by 30.5% during the third quarter. FMR LLC now owns 6,837,733 shares of the company’s stock worth $297,920,000 after acquiring an additional 1,598,602 shares during the period. State Street Corp lifted its holdings in Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company’s stock valued at $160,947,000 after purchasing an additional 88,922 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Doximity by 19.8% in the third quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock valued at $124,503,000 after buying an additional 472,565 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Doximity by 33.7% in the fourth quarter. Los Angeles Capital Management LLC now owns 870,322 shares of the company’s stock worth $46,466,000 after acquiring an additional 219,448 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Doximity by 4.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 753,001 shares of the company’s stock valued at $32,808,000 after acquiring an additional 31,966 shares during the period. 87.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DOCS has been the topic of a number of analyst reports. Stephens initiated coverage on shares of Doximity in a research report on Friday, December 20th. They issued an “equal weight” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Doximity from $30.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Barclays raised their price target on Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Truist Financial boosted their price target on Doximity from $35.00 to $49.00 and gave the stock a “hold” rating in a research report on Thursday, November 14th. Finally, Leerink Partnrs raised shares of Doximity from a “hold” rating to a “strong-buy” rating in a report on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.22.

Insider Buying and Selling at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now directly owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 37.40% of the company’s stock.

Doximity Stock Up 1.4 %

DOCS opened at $70.44 on Friday. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The firm has a 50 day moving average price of $61.91 and a 200-day moving average price of $50.61. The stock has a market capitalization of $13.15 billion, a price-to-earnings ratio of 70.44, a PEG ratio of 4.10 and a beta of 1.39.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.